Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ATHERSYS, INC / NEWATHX · Entity 95922 | Director | June 15, 2021 | June 15, 2021 |
| SELLAS Life Sciences Group, Inc.SLS · Entity 4313 | Director | January 07, 2026 | January 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ATHERSYS, INC / NEW
Report date June 15, 2021 · Filed June 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| NonQualified Stock Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.54 · Expires 2031-06-15 | Direct | 50,000 |
Reported balance
After 2021-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-15 · Grant · Acquired 50,000 · Balance 50,000 F1: Award of a nonqualified stock option. The option vests ratably on a quarterly basis over a one-year period. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of a nonqualified stock option. The option vests ratably on a quarterly basis over a one-year period.
SELLAS Life Sciences Group, Inc.
Report date January 07, 2026 · Filed January 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 154,400 |
Reported balance
After 2026-01-07 transaction · row 1
1 source rowRow 1 · 2026-01-07 · Grant · Acquired 50,000 · Balance 154,400 F1: The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 07, 2026 Filed Jan 9, 2026 21:31 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-002499 · tm262627-2_4seq1.xml · nonDerivative · entry 1 Kalin Katherine Bach · CIK 0001832671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,400 F1 · shares: The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 13:45 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | PurchaseCommon Stock | 63,400 | $1.59 | $100,806.00 |
DisclosureSEC source: 0001104659-25-114806 · tm2531880-1_4seq1.xml · nonDerivative · entry 1 Kalin Katherine Bach · CIK 0001832671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,400 F1 · price: The price reflects the weighted average purchase price of the shares of common stock purchased. These shares of common stock were purchased in multiple transactions at prices ranging from $1.555 to $1.625 per share. Ms. Kalin undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of common stock purchased at each price. Read SEC document |
| May 22, 2025 Filed May 22, 2025 20:05 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | PurchaseCommon Stock | 20,000 | $1.80 | $36,000.00 |
DisclosureSEC source: 0001104659-25-051980 · tm2515989-1_4seq1.xml · nonDerivative · entry 1 Kalin Katherine Bach · CIK 0001832671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,000 Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 22:31 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001104659-25-003496 · tm253166-3_4seq1.xml · derivative · entry 2 Kalin Katherine Bach · CIK 0001832671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2035-01-10 F2 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) January 10, 2026 (the first anniversary of the date of grant) or (y) the business day prior to the 2026 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 22:31 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-003496 · tm253166-3_4seq1.xml · nonDerivative · entry 1 Kalin Katherine Bach · CIK 0001832671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 F1 · shares: The Reporting Person received an award of 12,500 restricted stock units on January 10, 2025, which shall vest in full on December 1, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| January 22, 2024 Filed Jan 25, 2024 11:03 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001104659-24-006401 · tm243935-3_4seq1.xml · derivative · entry 2 Kalin Katherine Bach · CIK 0001832671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-01-22 F2 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) January 22, 2025 (the first anniversary of the date of grant) or (y) the business day prior to the 2025 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| January 22, 2024 Filed Jan 25, 2024 11:03 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-006401 · tm243935-3_4seq1.xml · nonDerivative · entry 1 Kalin Katherine Bach · CIK 0001832671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 F1 · shares: The Reporting Person received an award of 6,000 restricted stock units on January 22, 2024, which shall vest in full on December 1, 2024, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:10 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 9,500 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0001104659-23-010613 · tm235353d1_4seq1.xml · derivative · entry 2 Kalin Katherine Bach · CIK 0001832671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2033-02-02 F2 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) February 2, 2024 (the first anniversary of the date of grant) or (y) the business day prior to the 2024 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:10 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-010613 · tm235353d1_4seq1.xml · nonDerivative · entry 1 Kalin Katherine Bach · CIK 0001832671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · shares: The Reporting Person received an award of 2,500 restricted stock units on February 2, 2023, which shall vest in full on December 1, 2023, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| August 13, 2022 Filed Aug 16, 2022 20:08 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $3.10 | $0.00 |
DisclosureSEC source: 0001104659-22-091751 · tm2223585-1_4seq1.xml · derivative · entry 1 Kalin Katherine Bach · CIK 0001832671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2032-08-13 F1 · derivative.exercise_date: The shares subject to the option will fully vest on August 13, 2023. Read SEC document |
| June 15, 2021 Filed Jun 15, 2021 17:56 UTC | ATHERSYS, INC / NEW ATHX · Entity 95922 | GrantNonQualified Stock Option (right to purchase) · Derivative | 50,000 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0001368148-21-000078 · wf-form4_162379417108409.xml · derivative · entry 1 Kalin Katherine Bach · CIK 0001832671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: Award of a nonqualified stock option. The option vests ratably on a quarterly basis over a one-year period. Read SEC document |
| November 12, 2020 Filed Nov 17, 2020 16:15 UTC | ATHERSYS, INC / NEW ATHX · Entity 95922 | GrantNonQualified Stock Option (right to purchase) · Derivative | 100,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0001368148-20-000137 · wf-form4_160564773588881.xml · derivative · entry 1 Kalin Katherine Bach · CIK 0001832671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-11-12 F1 · derivative.exercise_date: Award of a nonqualified stock option. The option vests one-third on the one-year anniversary date from the date of grant, and the remainder vests on a quarterly basis over years two and three. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.